Literature DB >> 33400185

Is a single dose of preoperative antibiotic therapy effective for patients treated with megaendoprosthesis after metastatic bone tumour resection?

M Kiran1, J Alsousou2, N Dalal2, P Ralte2, G Kumar2, B Kapoor2.   

Abstract

Purpose The timing and number of doses of antibiotics required for megaendoprosthetic replacement (MPR) in metastatic bone disease (MBD) is a matter of debate. The aim of our study is to present the results of a prospective cohort of MPR for MBD receiving a single dose of antibiotic at induction of anaesthesia.
METHODS: All patients who underwent primary MPR in MBD were included in this prospective study. All penicillin-sensitive patients received one dose of cefuroxime 1.5gm intravenous at induction. In penicillin-allergic patients, teicoplanin 1.2gm and ciprofloxacin 500 mg intravenous was administered. The patients were followed up in the wound clinic and the specialist MBD clinic at 2 weeks, 3 months, 6 months and then annually. Data collected included demographics, primary tumours, surgical procedures, complications and duration of follow-up. All calculations were performed using SPSS® 25(IBM, USA). A p value ≤ 0.05 was considered to be significant.
RESULTS: There were 51 patients with a mean age of 65.4 years. Procedures included proximal femoral replacement (35), distal femoral replacement (7), proximal humeral replacement (4), distal humeral replacement (3) and total femoral replacement (2). Thirty-seven patients received cefuroxime, and fourteen patients received teicoplanin and ciprofloxacin at induction of anaesthesia. The deep infection rate was 1.9%. Thirty-seven patients died with a median survival of 10 months (1 to 51 months). Mean follow-up was 18.9 months (1 to 70 months).
CONCLUSION: Single dose of preoperative antibiotics at anaesthetic induction seems to be safe and effective for preoperative prophylaxis in orthopaedic oncology.
© 2021. Istituto Ortopedico Rizzoli.

Entities:  

Keywords:  Infection; Megaendoprosthetic replacement; Metastatic bone disease

Mesh:

Substances:

Year:  2021        PMID: 33400185     DOI: 10.1007/s12306-020-00692-6

Source DB:  PubMed          Journal:  Musculoskelet Surg        ISSN: 2035-5114


  25 in total

1.  The risks and benefits of radiotherapy with massive endoprosthetic replacement.

Authors:  L M Jeys; J S Luscombe; R J Grimer; A Abudu; R M Tillman; S R Carter
Journal:  J Bone Joint Surg Br       Date:  2007-10

2.  Periprosthetic infection in patients treated for an orthopaedic oncological condition.

Authors:  L M Jeys; R J Grimer; S R Carter; R M Tillman
Journal:  J Bone Joint Surg Am       Date:  2005-04       Impact factor: 5.284

3.  Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone.

Authors:  R J Grimer; B K Aydin; H Wafa; S R Carter; L Jeys; A Abudu; M Parry
Journal:  Bone Joint J       Date:  2016-06       Impact factor: 5.082

4.  Endoprostheses last longer than intramedullary devices in proximal femur metastases.

Authors:  Norah Harvey; Elke R Ahlmann; Daniel C Allison; Lingjun Wang; Lawrence R Menendez
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

Review 5.  Bone metastases: pathophysiology and management policy.

Authors:  O S Nielsen; A J Munro; I F Tannock
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

Review 6.  Treatment for long bone metastases based on a systematic literature review.

Authors:  Costantino Errani; Andreas F Mavrogenis; Luca Cevolani; Silvia Spinelli; Andrea Piccioli; Giulio Maccauro; Nicola Baldini; Davide Donati
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-09-20

7.  Prophylactic antibiotic regimens in tumor surgery (PARITY) survey.

Authors:  Khaled Hasan; Antonella Racano; Benjamin Deheshi; Forough Farrokhyar; Jay Wunder; Peter Ferguson; Ginger Holt; Herbert Schwartz; Brad Petrisor; Mohit Bhandari; Michelle Ghert
Journal:  BMC Musculoskelet Disord       Date:  2012-06-07       Impact factor: 2.362

8.  Low infection rate after tumor hip arthroplasty for metastatic bone disease in a cohort treated with extended antibiotic prophylaxis.

Authors:  Werner H Hettwer; Peter Frederik Horstmann; Thea Bechmann Hovgaard; Tomas Andreas Grum-Scwensen; Michael M Petersen
Journal:  Adv Orthop       Date:  2015-02-01

9.  Silver-Coated Hip Megaprosthesis in Oncological Limb Savage Surgery.

Authors:  F Donati; G Di Giacomo; S D'Adamio; A Ziranu; S Careri; Ma Rosa; G Maccauro
Journal:  Biomed Res Int       Date:  2016-08-23       Impact factor: 3.411

10.  Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study.

Authors:  Michelle Ghert; Benjamin Deheshi; Ginger Holt; R Lor Randall; Peter Ferguson; Jay Wunder; Robert Turcotte; Joel Werier; Paul Clarkson; Timothy Damron; Joseph Benevenia; Megan Anderson; Mark Gebhardt; Marc Isler; Sophie Mottard; John Healey; Nathan Evaniew; Antonella Racano; Sheila Sprague; Marilyn Swinton; Dianne Bryant; Lehana Thabane; Gordon Guyatt; Mohit Bhandari
Journal:  BMJ Open       Date:  2012-11-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.